Complexities of quality of life analysis in non-small cell lung cancer

Journal of Supportive Oncology

Volumn 5, Issue 1, 2007, Pages 30-31

  Temel, Jennifer ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; GEMCITABINE; PLACEBO;

ADVANCED CANCER; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; COUGHING; DYSPNEA; EMOTIONALITY; FATIGUE; FUNCTIONAL STATUS; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPATHY; QUALITY OF LIFE; RELIGION; REVIEW; SOCIAL ASPECT; SYMPTOM; WELLBEING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 33847682671     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Donaldson GW, Moinpour CM: Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol 2005;23:7380-7384.
2. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000;83:447-453.
3. Brown J, Thorpe H, Napp V, et al: Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol 2005;23:7417-7427.
4. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.